Overview

A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Zhejiang Doer Biologics Co., Ltd.